Body Revival® by Health Reactive is the first Ayurvedic product
tested on cancer survivors in official
ICMR-CTRI clinical trials.
Conducted by a senior team of oncologists from J.B. Roy State Ayurvedic and Medical College, Kolkata, the trial followed ICMR-CTRI guidelines and lasted for 11 months (Oct 2023 – Nov 2024).
Officially registered with the Clinical Trials Registry of India (CTRI/2023/11/059465) .
Significant improvements in physical and psychological well-being of breast cancer patients.
Patients reported better daily functionality, stamina, and energy levels.
Fewer chemotherapy and radiation-related side effects observed.
Better appetite, stamina, and reduced nausea, dizziness, constipation, and fatigue.
Marked decrease in liver enzyme levels with improved blood protein and haemoglobin counts.
The trial highlighted that “In-silico HER-2 receptor binding affinity with Symconoside B is similar to Tamoxifen.”
Tamoxifen is widely used for hormone receptor-positive breast cancer. This finding suggests that Body Revival® may complement traditional cancer treatments and enhance therapeutic efficacy.
This clinical trial isn’t just about one product—it’s about showing the world what Ayurveda can achieve. By successfully completing clinical trials, Body Revival has proven that Ayurvedic products can meet the highest standards of scientific research and bring hope to millions.